SCHEMBL5799291

SCHEMBL5799291

O=C(O)C(=NO)C(=O)CBr

nearest known ligand 0.55

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.40
TRPA1 O75762 1/20 0.32
OR51E2 Q9H255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10366257 0.79 TSHR (0.30) TSHR
SCHEMBL5811359 0.75
SCHEMBL10743466 0.74 GSK3B (0.32) TSHRTRPA1
SCHEMBL4884095 0.74 GSK3B (0.32) TSHRTRPA1
SCHEMBL4811123 0.74 GSK3B (0.32) TSHRTRPA1
SCHEMBL25312495 0.72 FFAR3 (0.40) OR51E2
SCHEMBL5431327 0.72 LDHA (0.42) TSHROR51E2
SCHEMBL10507701 0.72 TSHR (0.40) TSHROR51E2
SCHEMBL9651208 0.72 TSHR (0.40) TSHROR51E2
SCHEMBL9651203 0.72 TSHR (0.40) TSHROR51E2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114031575-B Preparation method of ethyl northioxomate 山东金城医药化工有限公司 2023-09-12 CN disclosed
WO-2006067803-A1 A NOVEL INTERMEDIATE FOR THE PREPARATION OF CEFEPIME LUPIN LIMITED (IN) 2006-06-29 WO disclosed
US-6846952-B2 Process for manufacture of a 4-bromo-2-oxyimino butyric acid and its derivatives LUPIN LIMITED (IN) 2005-01-25 US disclosed
US-20040054224-A1 Process for manufacture of a 4-bromo-2-oxyimino butyric acid and its derivatives LUPIN LIMITED (IN) 2004-03-18 US disclosed
WO-2003045899-A1 AN IMPROVED PROCESS FOR MANUFACTURE OF 4-BROMO-2-OXYIMINO BUTYRIC ACID AND ITS DERIVATIVES LUPIN LIMITED (IN) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040054224-A1 Process for manufacture of a 4-bromo-2-oxyimino butyric acid and its derivatives GABRB1, BBOX1, GABRB2 TSHR 682/4885TRPA1 3466/4885OR51E2 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.